Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

Pfizer's stock surged following a report of stronger-than-expected earnings, driven by robust sales of COVID-19 products and ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

David Hoskins wrote on X: “Pfizer made $31,400,000,000 in profits in 2022, so of course it needs to jack up the price of a lifesaving medication 2.6 times in 2023.” ...

Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than ...

Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of ...

Q2 2025 Management View Albert Bourla, Chairman and CEO, highlighted progress in R&D, expansion of the commercial portfolio, and improved margins, stating the company is “raising our adjusted diluted ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

WASHINGTON — Pfizer, the giant multinational drug company, said Tuesday that it would defer some price increases, after President Donald Trump thrashed the company in a Twitter post.

Trump sent a letter to 17 drug companies demanding a commitment to lower prices in the next 60 days through a series of ...